Clinical and Translational Research
Copyright ©The Author(s) 2024.
World J Clin Oncol. Jan 24, 2024; 15(1): 45-61
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.45
Table 1 Demographic and clinicopathological parameters of high and low HSPA4 expression group patients in The Cancer Genome Atlas - lung adenocarcinoma, n (%)
Characteristics
Low expression of HSPA4
High expression of HSPA4
P value
n269270
Pathologic T stage0.141
T199 (18.5)77 (14.4)
T2137 (25.6)155 (28.9)
T3 & T433 (6.2)35 (6.5)
Pathologic N stage0.028
N0189 (36.1)161 (30.8)
N141 (7.8)56 (10.7)
N2 & N331 (5.9)45 (8.6)
Pathologic stage0.012
Stage I163 (30.7)133 (25)
Stage II58 (10.9)67 (12.6)
Stage III & Stage IV43 (8.1)67 (12.6)
Gender0.410
Female149 (27.6)140 (26)
Male120 (22.3)130 (24.1)
Primary therapy outcome< 0.001
PD22 (4.9)49 (10.9)
SD & PR22 (4.9)22 (4.9)
CR186 (41.4)148 (33)
OS event0.002
Alive190 (35.3)157 (29.1)
Dead79 (14.7)113 (21)
Table 2 The COX regression analysis about clinicopathological characteristics associated with the survival of lung adenocarcinoma patients
CharacteristicsTotal (N)Univariate analysis
Multivariate analysis
Hazard ratio (95%CI)
P value
Hazard ratio (95%CI)
P value
Pathologic T stage527
T1176Reference Reference
T22851.507 (1.059-2.146)0.0231.086 (0.726-1.624)0.687
T3 & T4663.095 (1.967-4.868)< 0.0011.571 (0.827-2.984)0.168
Pathologic N stage514
N0345Reference Reference
N1962.293 (1.632-3.221)< 0.0011.293 (0.653-2.560)0.461
N2 & N3732.993 (2.057-4.354)< 0.0011.774 (0.906-3.471)0.094
Pathologic stage522
Stage I292Reference Reference
Stage II & stage III & stage IV2302.889 (2.141-3.897)< 0.0011.587 (0.789-3.193)0.195
Age520
≤ 65257Reference
> 652631.216 (0.910-1.625)0.186
Gender530
Female283Reference
Male2471.087 (0.816-1.448)0.569
Number pack years smoked363
< 40183Reference
≥ 401801.073 (0.753-1.528)0.697
HSPA4530
Low266Reference Reference
High2641.476 (1.104-1.972)0.0091.356 (0.967-1.901)0.078